Maria Teresa Carrì: A Pioneer in ALS Research and Her Lasting Legacy
"Remembering the life and work of Maria Teresa Carrì, a distinguished biochemist whose research significantly advanced our understanding of ALS and neurodegeneration."
On July 26th, the scientific community mourned the untimely passing of Maria Teresa Carrì, a Full Professor of Biochemistry at the University of Rome Tor Vergata. Her departure followed a courageous battle with an incurable disease, leaving behind a legacy of groundbreaking research and unwavering dedication to her field.
Carrì's journey into biochemistry was not her initial path. She originally trained in biology, earning her degree in 1981. However, her career took a pivotal turn when she joined a laboratory at the Second University of Rome (now University of Rome Tor Vergata), marking the beginning of her impactful contributions to the world of biochemistry.
At the time, Rome was emerging as a vibrant center for biochemistry research. An internationally recognized group of experts at the University of Rome La Sapienza were leading investigations into enzymology and protein structure-function relationships. Carrì's decision to join this dynamic environment set the stage for her future discoveries.
Current ALS Burden
The CDC's National ALS Registry reports that calendar year 2018 is the most current prevalence data available through its dashboard. A separate report citing a CDC Registry study published in January 2025 estimated that 32,893 people were living with ALS in the United States in 2022, corresponding to a prevalence of 9.9 per 100,000 people. The Registry also provides a platform connecting people living with ALS with clinicians and researchers, while participation enables people to contribute to research and be counted.
Clinical Approaches and Limits
ALS care generally relies on clinical assessment, supportive management, and treatments intended to address symptoms or slow progression. Because ALS is heterogeneous and progresses differently among individuals, clinicians may need to adapt care over time. Existing approaches remain imperfect, and the available evidence does not support presenting any single method as universally effective.
A Developing Research Tradition
ALS research has developed through successive efforts to characterize the disease, understand its biological mechanisms, and improve clinical care. The field's history is best viewed as cumulative rather than complete, because important questions about disease causes and progression remain unresolved. Foundational discoveries have informed later research, but their practical benefits have not yet eliminated the disease's substantial clinical burden.
Unraveling the Mysteries of Superoxide Dismutase (SOD1) and ALS
Carrì's research initially focused on Cu, Zn-Superoxide dismutase (SOD1), a protein extensively studied for its structure and catalytic action. She established a new laboratory dedicated to exploring the potential of molecular biology. This led to a specific project aligned with the biochemical interests of the Tor Vergata Department of Biology, where researchers aimed to understand the central role of oxygen and energy metabolism in cell biology.
- Gene Manipulation: Modifying the genetic code of SOD1 to produce enzymes with specific alterations.
- Cloning and Expression: Creating copies of the modified genes and producing the corresponding enzymes in the lab.
- Functional Analysis: Studying how the altered enzymes behaved and interacted within cells.
Emerging Research Directions
Recent reviews describe ALS as a multifactorial neurodegenerative disorder shaped by interactions among genetic, environmental, developmental, and resilience-related factors. Research is also examining non-motor symptoms alongside the disease's better-known effects on the motor system. Genetic and RNA biology studies are investigating the pathogenetic basis of ALS, while therapeutic reviews are evaluating drugs and candidates aimed at diverse mechanisms because current treatments have limited efficacy in slowing progression.
Persistent Therapeutic Gaps
The reviewed literature consistently presents ALS as a severe, progressive disorder involving motor-neuron loss, disability, paralysis, and eventual death. Despite sustained research, treatment options remain limited, and current therapies have not resolved the disease's marked clinical heterogeneity. Research on C9ORF72-related ALS and frontotemporal dementia also illustrates that fundamental mechanistic questions, including whether toxic gain of function drives disease, remain under investigation.
Comparing ALS Research Strategies
ALS research approaches differ in emphasis, including clinical characterization, molecular mechanism studies, and therapeutic development. These approaches are complementary because the disease's heterogeneity makes it difficult to connect one biological explanation or treatment strategy to every patient. Comparisons should therefore account for differences in disease presentation, proposed mechanisms, and the outcomes used to judge therapeutic success.
A Lasting Impact on ALS Research
Maria Teresa Carrì's contributions extended beyond her laboratory. She actively promoted ALS research nationally and internationally, serving on funding committees, expert panels, and editorial boards. Her dedication, determination, and collaborative spirit made her a respected figure in the scientific community. Her work continues to inspire researchers striving to unravel the complexities of ALS and find effective treatments.
A Complex Research Challenge
Taken together, the available material portrays ALS as a complex neurodegenerative disease with multiple interacting causes and highly variable manifestations. Progress in genetics, RNA biology, and therapeutic discovery has expanded the field's possibilities, but limited treatment efficacy remains a central constraint. A balanced interpretation recognizes meaningful scientific advances while avoiding the conclusion that ALS is close to being solved.
Next Research Frontiers
Future ALS research is likely to focus on clarifying disease mechanisms, identifying meaningful biological subgroups, and developing treatments that address more than one pathological pathway. Genetic and RNA-based strategies represent important areas of investigation, but their clinical value will depend on further evidence. Continued work will also need to connect molecular discoveries with outcomes that matter to people living with ALS.
Systemic Complexity
ALS was historically viewed as an isolated muscle disease, but the field increasingly recognizes systemic effects beyond voluntary muscles. Its complexity and heterogeneous manifestations continue to challenge research and treatment, even after recent drug approvals. Recent conceptual and methodological advances have improved understanding of ALS and the ALS-frontotemporal dementia spectrum, while the need for more effective therapies remains critical.
Patients, Caregivers, and Evidence
ALS progressively weakens the neurons controlling voluntary movement, affecting a person's ability to walk, talk, move, swallow, and eventually breathe independently. Because ALS is rare, understanding its natural history depends on collaboration among clinical centers, regions, and countries so that patients, caregivers, clinicians, and researchers can contribute to shared evidence. The ALS/MND Natural History consortium demonstrates this approach by collecting medical history, medication, longitudinal outcomes, survival, and demographic data from nine ALS clinics.